Loading…
← CockpitCompetitor Analysis › 002940.SZ Zhejiang Anglikang Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Zhejiang Anglikang Pharmaceutical Co. Ltd. Class A002940.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum laggard 16
Mkt cap
$612M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$49.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.3 pp
WACC 6.5%
Hurdle
+8 pp
Req g minus delivered
Close · CNYCN¥20.85
1D-5.8%
1W-17.5%
1M-11.8%
3M-22.8%
6M-51.8%
YTD-37.8%
1Y-48.9%
ATR %7.0%
52w lowhigh57.4% off high

What Zhejiang Anglikang Pharmaceutical does

Employees: 1,236

Zhejiang Anglikang Pharmaceutical at a glance

Size Zhejiang Anglikang Pharmaceutical (002940.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $612M, the 3195th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥20.85 on 18 Nov 2026.

Performance Over six months the shares fell 51.8%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue fell 13.5% over the last twelve months (peer median +4.6%); the operating margin is 10.0% (peer median 4.1%).

Valuation It trades at 3.3× enterprise value to sales against a peer median of 3.3× (8th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.3 points above its cost of capital (6.5% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 75002940.SZ 50
Six months, rebased to 100: Zhejiang Anglikang Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Anglikang Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.27BCN¥1.42BCN¥1.52BCN¥1.61BCN¥1.55B
Revenue growth—-7%-5%+4%—
Gross profitCN¥529MCN¥527MCN¥574MCN¥680MCN¥864M
EBITDAn/aCN¥228MCN¥204MCN¥242MCN¥196M
Net incomeCN¥110MCN¥125MCN¥80.3MCN¥138MCN¥127M
Free cash flowCN¥166MCN¥196MCN¥162MCN¥155MCN¥117M
Capital expenditureCN¥58.3MCN¥49.9MCN¥94.5MCN¥125MCN¥68.8M
Total debtCN¥704MCN¥733MCN¥805MCN¥796MCN¥570M

Quarterly statements and history in the cockpit →

Zhejiang Anglikang Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%300194603567ORCHPHARMA0027931857504105OLMA301211DBV300233BCAX600976IMMX300878300147CGEM002940.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Anglikang Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×10×20×300194603567ORCHPHARMA002793185750300233301096ABUS3008783001474123002940.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Anglikang Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%30019460356700279318575041053002333001474123002940.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Anglikang Pharmaceutical is the large dot.

Zhejiang Anglikang Pharmaceutical competitors and peer comparison

How Zhejiang Anglikang Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Anglikang Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002940.SZPeer medianRank in peer set
1-month return-11.8%-10.2%10th lowest of 20
6-month return-51.8%-26.6%2nd lowest of 20
Distance from 52-week high-57.4%-41.0%6th lowest of 20
Revenue growth (TTM)-13.5%+4.6%2nd lowest of 15
Operating margin10.0%4.1%3rd highest of 14
EV / Sales3.3×3.3×8th cheapest of 15
Growth the price implies (Req g, 7 yrs)10.1%-0.6%4th most demanding of 10
Growth delivered (Del g)+2.1%-1.6%5th highest of 10
Hurdle (Req g minus delivered)+8.1 pp+16.9 pp5th least demanding of 10
ROIC minus cost of capital+0.3 pp-4.8 pp3rd highest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a

Questions

Which companies are Zhejiang Anglikang Pharmaceutical's closest peers?
The cockpit's peer set: Fuan Pharmaceutical (Group) (300194.SZ), HeiLongJiang ZBD Pharmaceutical (603567.SS), Orchid Pharma (ORCHPHARMA.NS), Achieve Life Sciences (QUIT), Luoxin Pharmaceuticals Group Stock (002793.SZ), Chongkundang (185750.KS), TTY Biopharm (4105.TWO), Olema Pharmaceuticals (OLMA).
Is Zhejiang Anglikang Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.3× against a peer median of 3.3×, 8th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhejiang Anglikang Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -51.8% against -26.6% for the median peer; over one year -48.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.